Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 1
2007 11
2008 11
2009 4
2011 2
2012 1
2013 1
2015 4
2016 2
2018 1
2019 2
2021 4
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Huston A, et al. Among authors: hatjiharissi e. Clin Cancer Res. 2024 Feb 16;30(4):922. doi: 10.1158/1078-0432.CCR-24-0181. Clin Cancer Res. 2024. PMID: 38362725 No abstract available.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Katodritou E, Hatjiharissi E, Malandrakis P, Verrou E, Golfinopoulos S, Migkou M, Manousou K, Delimpasi S, Symeonidis A, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: hatjiharissi e. Am J Hematol. 2024 Mar;99(3):396-407. doi: 10.1002/ajh.27206. Epub 2024 Jan 31. Am J Hematol. 2024. PMID: 38298023 Clinical Trial.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Kastritis E, Terpos E, Symeonidis A, Labropoulou V, Delimpasi S, Mancuso K, Zamagni E, Katodritou E, Rivolti E, Kyrtsonis MC, Roussou M, Fotiou D, Theodorakakou F, Ntanasis-Stathopoulos I, Hatjiharissi E, Kanellias N, Migkou M, Cheliotis G, Manousou K, Gavriatopoulou M, Dimopoulos MA. Kastritis E, et al. Among authors: hatjiharissi e. Am J Hematol. 2023 Sep;98(9):E226-E229. doi: 10.1002/ajh.27001. Epub 2023 Jun 21. Am J Hematol. 2023. PMID: 37340832 Clinical Trial. No abstract available.
MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.
Katsarou A, Trasanidis N, Ponnusamy K, Kostopoulos IV, Alvarez-Benayas J, Papaleonidopoulou F, Keren K, Sabbattini PMR, Feldhahn N, Papaioannou M, Hatjiharissi E, Sudbery IM, Chaidos A, Caputo VS, Karadimitris A. Katsarou A, et al. Among authors: hatjiharissi e. Blood Adv. 2023 Nov 14;7(21):6395-6410. doi: 10.1182/bloodadvances.2023009772. Blood Adv. 2023. PMID: 37224458 Free PMC article.
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories.
Gkoliou G, Agathangelidis A, Karakatsoulis G, Lalayanni C, Papalexandri A, Medina A, Genuardi E, Chlichlia K, Hatjiharissi E, Papaioannou M, Terpos E, Jimenez C, Sakellari I, Ferrero S, Ladetto M, Sanz RG, Belessi C, Stamatopoulos K. Gkoliou G, et al. Among authors: hatjiharissi e. Front Oncol. 2023 Feb 8;13:1123029. doi: 10.3389/fonc.2023.1123029. eCollection 2023. Front Oncol. 2023. PMID: 36845709 Free PMC article.
A novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report.
Doumas A, Zegkos T, Parcharidou D, Gossios T, Ntelios D, Chatzileontiadou S, Papanastasiou E, Hatjiharissi E, Iakovou I, Efthimiadis GK. Doumas A, et al. Among authors: hatjiharissi e. Hell J Nucl Med. 2022 May-Aug;25(2):216-219. doi: 10.1967/s002449912483. Epub 2022 Aug 3. Hell J Nucl Med. 2022. PMID: 35913870 Free article.
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
Terpos E, Ntanasis-Stathopoulos I, Kastritis E, Hatjiharissi E, Katodritou E, Eleutherakis-Papaiakovou E, Verrou E, Gavriatopoulou M, Leonidakis A, Manousou K, Delimpasi S, Malandrakis P, Kyrtsonis MC, Papaioannou M, Symeonidis A, Dimopoulos MA. Terpos E, et al. Among authors: hatjiharissi e. Cancers (Basel). 2022 Jun 2;14(11):2768. doi: 10.3390/cancers14112768. Cancers (Basel). 2022. PMID: 35681747 Free PMC article.
Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
Karakatsanis SJ, Bouzani M, Symeonidis A, Angelopoulou MK, Papageorgiou SG, Michail M, Gainaru G, Kourti G, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Kanellias N, Dimopoulou MN, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsonis MC, Anargyrou K, Papaioannou M, Hatjiharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Stefanoudaki E, Zikos P, Tsirigotis P, Tsourouflis G, Assimakopoulou T, Verrou E, Papadaki H, Lampropoulou P, Dimopoulos MA, Pappa V, Konstantopoulos K, Karmiris T, Roussou P, Panayiotidis P, Pangalis GA, Vassilakopoulos TP; Hellenic Cooperative Lymphoma Group. Karakatsanis SJ, et al. Among authors: hatjiharissi e. In Vivo. 2022 May-Jun;36(3):1302-1315. doi: 10.21873/invivo.12831. In Vivo. 2022. PMID: 35478115 Free PMC article.
55 results